Last reviewed · How we verify
Camrelizumab ＋Immunotherapy
Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Advanced or metastatic non-small cell lung cancer (in combination with chemotherapy or other immunotherapy), Hepatocellular carcinoma (in combination with other immunotherapy agents), Other solid tumors in phase 3 development.
At a glance
| Generic name | Camrelizumab ＋Immunotherapy |
|---|---|
| Sponsor | Peking University Cancer Hospital & Institute |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and enhances cytotoxic T cell proliferation and activation. When combined with other immunotherapy agents, it may provide synergistic anti-tumor effects through complementary immune checkpoint mechanisms.
Approved indications
- Advanced or metastatic non-small cell lung cancer (in combination with chemotherapy or other immunotherapy)
- Hepatocellular carcinoma (in combination with other immunotherapy agents)
- Other solid tumors in phase 3 development
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer (PHASE2)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (PHASE3)
- Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (PHASE2)
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial (PHASE3)
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma (PHASE2)
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (PHASE2)
- 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: